These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 33277568)
1. Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects. Cho JM; Yang EH; Quan W; Nam EH; Cheon HG Sci Rep; 2020 Dec; 10(1):21280. PubMed ID: 33277568 [TBL] [Abstract][Full Text] [Related]
3. Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice. Panaro BL; Coppage AL; Beaudry JL; Varin EM; Kaur K; Lai JH; Wu W; Liu Y; Bachovchin WW; Drucker DJ Mol Metab; 2019 Jan; 19():65-74. PubMed ID: 30477988 [TBL] [Abstract][Full Text] [Related]
4. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Ryabtsova O; Jansen K; Van Goethem S; Joossens J; Cheng JD; Lambeir AM; De Meester I; Augustyns K; Van der Veken P Bioorg Med Chem Lett; 2012 May; 22(10):3412-7. PubMed ID: 22525314 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760 [TBL] [Abstract][Full Text] [Related]
6. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786 [TBL] [Abstract][Full Text] [Related]
7. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. Tsai TY; Yeh TK; Chen X; Hsu T; Jao YC; Huang CH; Song JS; Huang YC; Chien CH; Chiu JH; Yen SC; Tang HK; Chao YS; Jiaang WT J Med Chem; 2010 Sep; 53(18):6572-83. PubMed ID: 20718420 [TBL] [Abstract][Full Text] [Related]
15. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. Poplawski SE; Lai JH; Li Y; Jin Z; Liu Y; Wu W; Wu Y; Zhou Y; Sudmeier JL; Sanford DG; Bachovchin WW J Med Chem; 2013 May; 56(9):3467-77. PubMed ID: 23594271 [TBL] [Abstract][Full Text] [Related]
16. Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor. Jung HJ; Nam EH; Park JY; Ghosh P; Kim IS Bioorg Med Chem Lett; 2021 Apr; 37():127846. PubMed ID: 33571650 [TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic activities of Gegen Qinlian Decoction in high-fat diet combined with streptozotocin-induced diabetic rats and in 3T3-L1 adipocytes. Zhang CH; Xu GL; Liu YH; Rao Y; Yu RY; Zhang ZW; Wang YS; Tao L Phytomedicine; 2013 Feb; 20(3-4):221-9. PubMed ID: 23219338 [TBL] [Abstract][Full Text] [Related]
18. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase. Jackson KW; Christiansen VJ; Yadav VR; Silasi-Mansat R; Lupu F; Awasthi V; Zhang RR; McKee PA Neoplasia; 2015 Jan; 17(1):43-54. PubMed ID: 25622898 [TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. Edosada CY; Quan C; Wiesmann C; Tran T; Sutherlin D; Reynolds M; Elliott JM; Raab H; Fairbrother W; Wolf BB J Biol Chem; 2006 Mar; 281(11):7437-44. PubMed ID: 16410248 [TBL] [Abstract][Full Text] [Related]
20. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? Juillerat-Jeanneret L; Tafelmeyer P; Golshayan D Expert Opin Ther Targets; 2017 Oct; 21(10):977-991. PubMed ID: 28829211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]